Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.

Benitec Biopharma Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

HAYWARD, CALIF., MARCH 25, 2025 (GLOBE NEWSWIRE) -- BENITEC BIOPHARMA INC. (NASDAQ: BNTC) (BENITEC OR THE COMPANY), A CLINICAL-STAGE, GENE THERAPY-FOCUSED, BIOTECHNOLOGY COMPANY DEVELOPING NOVEL GENETIC MEDICINES BASED ON ITS PROPRIETARY DNA-DIRECTED RNA INTERFERENCE (DDRNAI) SILENCE AND REPLACE PLATFORM, TODAY ANNOUNCED THE PRICING OF ITS UNDERWRITTEN OFFERING OF 1,443,000 SHARES OF ITS COMMON STOCK (OR PRE-FUNDED WARRANTS TO PURCHASE COMMON STOCK IN LIEU THEREOF) AND A CONCURRENT REGISTERED DIRECT OFFERING OF 900,000 SHARES OF ITS COMMON STOCK WITH LONG-TERM INVESTOR SUVRETTA CAPITAL.

BENITEC BIOPHARMA INC. ANNOUNCES PRICING OF $30 MILLION COMMON STOCK OFFERING

-FIFTH SUBJECT IN BB-301 PHASE 1B/2A CLINICAL TREATMENT STUDY SAFELY TREATED IN FEBRUARY 2025- -INTERIM CLINICAL STUDY UPDATE TO BE PRESENTED IN LATE-BREAKING ORAL PRESENTATION AT THE 2025 MUSCULAR DYSTROPHY ASSOCIATION CLINICAL & SCIENTIFIC CONFERENCE ON MARCH 19, 2025- HAYWARD, CALIF., FEB. 14, 2025 (GLOBE NEWSWIRE) -- BENITEC BIOPHARMA INC. (NASDAQ: BNTC) (BENITEC OR COMPANY), A CLINICAL-STAGE, GENE THERAPY-FOCUSED, BIOTECHNOLOGY COMPANY DEVELOPING NOVEL GENETIC MEDICINES BASED ON ITS PROPRIETARY SILENCE AND REPLACE DNA-DIRECTED RNA INTERFERENCE ("DDRNAI") PLATFORM, TODAY ANNOUNCED FINANCIAL RESULTS FOR ITS SECOND FISCAL QUARTER ENDED DECEMBER 31, 2024.

BENITEC BIOPHARMA RELEASES SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES OPERATIONAL UPDATE

HAYWARD, CALIF., NOV. 26, 2024 (GLOBE NEWSWIRE) -- BENITEC BIOPHARMA INC. (NASDAQ: BNTC) (BENITEC OR THE COMPANY), A CLINICAL-STAGE, GENE THERAPY-FOCUSED, BIOTECHNOLOGY COMPANY DEVELOPING NOVEL GENETIC MEDICINES BASED ON ITS PROPRIETARY SILENCE AND REPLACE DNA-DIRECTED RNA INTERFERENCE ("DDRNAI") PLATFORM, TODAY ANNOUNCED THAT ITS MANAGEMENT TEAM WILL PARTICIPATE IN THE FOLLOWING UPCOMING INVESTOR CONFERENCES.

BENITEC BIOPHARMA TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES IN DECEMBER

-POSITIVE 270-DAY INTERIM CLINICAL STUDY DATA FOR THE FIRST SUBJECT AND POSITIVE 180-DAY INTERIM CLINICAL STUDY DATA FOR THE SECOND SUBJECT TREATED WITH THE LOW-DOSE OF BB-301 IN THE PHASE 1B/2A CLINICAL TREATMENT STUDY REPORTED IN OCTOBER AS A LATE-BREAKING ORAL PRESENTATION AT THE 29 TH ANNUAL CONGRESS OF THE WORLD MUSCLE SOCIETY-

BENITEC BIOPHARMA RELEASES FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES OPERATIONAL UPDATE

HAYWARD, CALIF., NOV. 04, 2024 (GLOBE NEWSWIRE) -- BENITEC BIOPHARMA INC. (NASDAQ: BNTC) (BENITEC OR THE COMPANY), A CLINICAL-STAGE, GENE THERAPY-FOCUSED, BIOTECHNOLOGY COMPANY DEVELOPING NOVEL GENETIC MEDICINES BASED ON ITS PROPRIETARY SILENCE AND REPLACE DNA-DIRECTED RNA INTERFERENCE ("DDRNAI") PLATFORM, TODAY ANNOUNCES CEO JEREL A. BANKS, M.D., PH.D. WILL BE PARTICIPATING IN THE GUGGENHEIM SECURITIES HEALTHCARE CONFERENCE, TAKING PLACE IN BOSTON FROM NOVEMBER 11-13, 2024.

BENITEC BIOPHARMA CEO TO PARTICIPATE IN THE GUGGENHEIM SECURITIES HEALTHCARE CONFERENCE

-MANAGEMENT PLANS TO HOST AN INVESTOR WEBCAST ON OCTOBER 14 TH AT 8:30 AM EDT TO PROVIDE AN UPDATE FOR THE BB-301 PHASE 1B/2A CLINICAL STUDY, DETAILS BELOW-

BENITEC BIOPHARMA ANNOUNCES UPDATED INVESTOR WEBCAST INFORMATION

-SUBJECT 1 AND SUBJECT 2 EXPERIENCED DURABLE, CLINICALLY MEANINGFUL IMPROVEMENTS IN SWALLOWING AT 9-MONTHS AND 6-MONTHS POST-BB-301 TREATMENT, RESPECTIVELY, WITH SUBJECT 2 ACHIEVING A SYDNEY SWALLOW QUESTIONNAIRE SCORE REPRESENTATIVE OF CLINICALLY NORMAL SWALLOWING-

BENITEC BIOPHARMA REPORTS POSITIVE DATA FROM TWO SUBJECTS TREATED WITH LOW-DOSE BB-301 IN PHASE 1B/2A STUDY PRESENTED AT 29TH ANNUAL CONGRESS OF THE WORLD MUSCLE SOCIETY

-POSITIVE 90-DAY AND 180-DAY INTERIM CLINICAL TRIAL DATA FOR THE FIRST OCULOPHARYNGEAL MUSCULAR DYSTROPHY (OPMD) SUBJECT DOSED WITH THE LOW-DOSE OF BB-301 IN THE PHASE 1B/2A CLINICAL TREATMENT STUDY REPORTED IN APRIL AND JULY-

BENITEC BIOPHARMA RELEASES FULL YEAR 2024 FINANCIAL RESULTS AND PROVIDES OPERATIONAL UPDATE

HAYWARD, CALIF., SEPT. 18, 2024 (GLOBE NEWSWIRE) -- BENITEC BIOPHARMA INC. (NASDAQ: BNTC) (BENITEC OR THE COMPANY), A CLINICAL-STAGE, GENE THERAPY-FOCUSED, BIOTECHNOLOGY COMPANY DEVELOPING NOVEL GENETIC MEDICINES BASED ON ITS PROPRIETARY SILENCE AND REPLACE DNA-DIRECTED RNA INTERFERENCE ("DDRNAI") PLATFORM, TODAY ANNOUNCED THAT A LATE BREAKING ABSTRACT ON BB-301 WAS ACCEPTED FOR ORAL PRESENTATION AT THE 29TH ANNUAL CONGRESS OF THE WORLD MUSCLE SOCIETY, TAKING PLACE IN PRAGUE, CZECH REPUBLIC FROM OCTOBER 8-12, 2024. THE LATE BREAKING ABSTRACT ENTITLED INTERIM CLINICAL DATA SUMMARY: A PHASE 1B/2A OPEN-LABEL, DOSE ESCALATION STUDY TO EVALUATE THE SAFETY AND CLINICAL ACTIVITY OF INTRAMUSCULAR DOSES OF AN AAV9-BASED GENE THERAPY (BB-301) ADMINISTERED TO SUBJECTS WITH OCULOPHARYNGEAL MUSCULAR DYSTROPHY (OPMD) WITH DYSPHAGIA WILL BE PRESENTED ON OCTOBER 12, 2024.

BENITEC BIOPHARMA ANNOUNCES LATE BREAKING ORAL ABSTRACT PRESENTATION ON BB-301 PHASE 1B/2A CLINICAL STUDY AT THE 29TH ANNUAL CONGRESS OF THE WORLD MUSCLE SOCIETY

-THE POST-DOSE AVERAGE VALUES FOR TOTAL PHARYNGEAL RESIDUE (I.E., THE AMOUNT OF SOLID FOOD OR LIQUID MATERIAL REMAINING IN THE PHARYNX AFTER THE FIRST SWALLOW) REMAINED MEANINGFULLY REDUCED AT THE 180-DAY POST-DOSE ASSESSMENT FOLLOWING THE ADMINISTRATION OF THE LOW DOSE OF GENE THERAPY BB-301 AS COMPARED TO THE PRE-DOSE AVERAGE VALUES RECORDED FOR SUBJECT 1 DURING THE OPMD NATURAL HISTORY STUDY-

BENITEC BIOPHARMA REPORTS CONTINUED DURABLE IMPROVEMENTS IN THE RADIOGRAPHIC ASSESSMENTS OF SWALLOWING EFFICIENCY AND THE SUBJECT-REPORTED OUTCOME INSTRUMENT AT THE 180-DAY TIMEPOINT FOR FIRST OPMD SUBJECT TREATED WITH LOW-DOSE BB-301 IN PHASE 1B/2A STUDY

Benitec Biopharma Inc.

BNTC

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Benitec Biopharma Inc.

BNTC.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

BNTC